210 related articles for article (PubMed ID: 12688405)
1. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Tachikawa H; Kodama M; Hui L; Yoshida T; Hayashi M; Abe S; Kashimura T; Kato K; Hanawa H; Watanabe K; Nakazawa M; Aizawa Y
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
[TBL] [Abstract][Full Text] [Related]
3. Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis.
Liu X; Zhu X; Wang A; Fan H; Yuan H
Int J Cardiol; 2009 Nov; 137(3):282-8. PubMed ID: 19896742
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
[TBL] [Abstract][Full Text] [Related]
5. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats].
Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.
Sukumaran V; Watanabe K; Veeraveedu PT; Thandavarayan RA; Gurusamy N; Ma M; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
Exp Biol Med (Maywood); 2010 Nov; 235(11):1338-46. PubMed ID: 20876084
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Hayashi N; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models.
Yamamoto S; Hayashi N; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):630-4. PubMed ID: 9205777
[TBL] [Abstract][Full Text] [Related]
9. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
Wang T; Yin KS; Liu KY; Lu GJ; Li YH; Chen JD
Chin Med J (Engl); 2008 Nov; 121(22):2312-9. PubMed ID: 19080339
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
11. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
[TBL] [Abstract][Full Text] [Related]
12. [The effect of angiotensin II type 1 receptor blocker valsartan in preventing hepatic fibrosis induced by dimethylnitrosamine in rats].
Shen FJ; Zhu YK; Jia JD; Ma H; Wang BE
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):605-8. PubMed ID: 15504291
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Watanabe K; Juan W; Narasimman G; Ma M; Inoue M; Saito Y; Wahed MI; Nakazawa M; Hasegawa G; Naito M; Tachikawa H; Tanabe N; Kodama M; Aizawa Y; Yamamoto T; Yamaguchi K; Takahashi T
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S93-7. PubMed ID: 12693379
[TBL] [Abstract][Full Text] [Related]
14. The angiotensin type 1 receptor antagonist valsartan attenuates pathological ventricular hypertrophy induced by hyperhomocysteinemia in rats.
Kassab S; Garadah T; Abu-Hijleh M; Golbahar J; Senok S; Wazir J; Gumaa K
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):206-11. PubMed ID: 17318789
[TBL] [Abstract][Full Text] [Related]
15. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Richer C; Fornes P; Domergue V; De Gasparo M; Giudicelli JF
J Card Fail; 2001 Sep; 7(3):269-76. PubMed ID: 11561229
[TBL] [Abstract][Full Text] [Related]
16. Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Okuda S; Yano M; Doi M; Oda T; Tokuhisa T; Kohno M; Kobayashi S; Yamamoto T; Ohkusa T; Matsuzaki M
Circulation; 2004 Feb; 109(7):911-9. PubMed ID: 14757694
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant.
White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L
Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110
[TBL] [Abstract][Full Text] [Related]
18. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
20. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
